复星医药获两药品注册申请受理

财中社
10 Feb

财中社2月10日电复星医药(600196/02196)发布公告,控股子公司桂林南药股份有限公司和上海朝晖药业有限公司分别就注射用硫酸多黏菌素B和盐酸拉贝洛尔注射液的药品注册上市申请获得国家药品监督管理局受理。药品1拟用于对常规疗法耐药的革兰氏阴性菌感染,药品2则用于严重高血压及麻醉过程中控制低血压。截至2024年12月,针对药品1和药品2的累计研发投入分别约为488万元和209万元。根据...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10